As the novel coronavirus COVID-19 continues to spread in the United States, many people are understandably concerned about access to their medications. Health officials and medical professionals working in federal, state and local governments recommend that high-risk individuals with underlying health conditions such as Type 1 Diabetes, stock up on their prescription medications, in addition to practicing basic hygiene and avoiding crowded places.
With the COVID-19 coronavirus continuing to spread and disrupt daily life, supply chains and medical operations, there is an increasing need for access to vital basics such as hand sanitizer. Through an ongoing partnership with MassBio, we were able to answer the call – along with numerous other organizations – as to how we can …
People living with type 1 diabetes learn, in many ways, to be research scientists and investigators of their own lives. We learn how slices of pizza or a plate of spaghetti affects our blood sugar, and how to mediate those effects with multiple boluses of insulin or a long-lasting dose. We discover precisely how much sugar we need to stay steady during an intense workout session. In doing so, we begin to learn about the meaning and applications of real-world data and evidence. Modern medical and scientific research takes several different approaches to investigation, from randomized, controlled clinical trials to longitudinal, observational studies that examine how people live with various conditions and therapies in the real world.
The most widely-reported and potentially momentous story of the moment is the novel COVID-19 coronavirus, a respiratory pathogen that has already infected at least 100,000 people around the globe and killed at least 4,300.
Research on type 1 diabetes often centers on its health impacts, but people with type 1 diabetes have long said that such research only paints half of the picture, and that there are many more hidden costs to life with the condition.
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
The T1D Exchange Registry launched last year, and it’s begun to provide a fascinating and vital look into some of the more detailed aspects of life with type 1 diabetes. From your age of diagnosis to frequency of testing, we’ve learned more about how you’re living, working, and caring for diabetes across the country.